Pozen Trexima NDA filing relieves MT 100 headache
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pozen's submission of an NDA for migraine treatment Trexima (sumatriptan/naproxen) Aug. 8, anticipated to receive a standard review, sets a user fee goal date of June 8, 2006. The submission follows a negative review of Pozen's MT 100 (naproxen/metoclopramide) combination migraine agent by FDA's Peripheral & Central Nervous System Drugs Advisory Committee Aug. 4. Pozen discontinued U.S. development of MT 100 the day after the meeting. GSK will market Trexima upon approval under a June 2003 agreement. In Phase III studies, Trexima demonstrated statistical superiority for the primary endpoint of sustained pain-free response over the individual drugs sumatriptan and naproxen. In addition, Phase III studies showed Trexima was statistically superior to its individual components in two-hour pain response endpoints, the company said...
You may also be interested in...
Complete response for Pozen’s Trexima
FDA has accepted Pozen's amended response to an "approvable" letter the firm received Aug. 1 for its migraine candidate Trexima (sumatriptan and naproxen sodium). The agency deemed the application complete, setting the clock for an April 15, 2008, user fee date, Pozen announces Nov. 1. The company submitted the NDA Aug. 8, 2005. GSK will market Trexima upon approval under a June 2003 agreement (1Pharmaceutical Approvals Monthly August 2005, p. 2). In Phase III studies, Trexima demonstrated statistical superiority for the primary endpoint of sustained pain-free response over the individual drugs sumatriptan and naproxen...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.